Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS and fertility: new study looks at ovarian health in young women

NCT ID NCT07164924

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether multiple sclerosis (MS) and its treatments affect a woman's egg supply. Researchers measured a hormone called AMH in blood samples from over 800 women with MS or a related condition. The goal was to see if disease activity or medications impact ovarian reserve, which is key for fertility. The findings could help guide decisions about fertility preservation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better counsel women with MS about their fertility and when to consider fertility preservation.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

800 people

The number who actually took part.

Started

Jan 2018

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women, with age between 18 at 35, with a diagnosis of MS or NMOSD , present in EDMUS database, which has a blood sample in the OFSEP cohort

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female * Diagnosis of MS (including CIS) or NMOSD * Aged 18 to 35 years old at blood sample collection Exclusion Criteria: * Diagnosis of radiologically isolated syndrome (RIS) * Age less than18 or more than 35. * History of ovarian surgery * Endometriosis * Hypergonadotropin amenohrrea * Any associated known autoimmune disease other than MS * Previous MS treatment with immunosuppressive agents such as azathioprine, cyclophosphamide, mitoxantrone, bone marrow transplantation * Previous treatment with gonadotoxic drugs (eg chemotherapy)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder multiple sclerosis neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fertility Multiple sclerosis Neuromyelitis optica spectrum disorders

Contacts and locations

Locations

  • AP-HM

    Marseille, France

  • AP-HP - Créteil

    Créteil, France

  • CHI Poissy- Saint-Germain-en-Laye

    Poissy, France

  • CHU Amiens

    Amiens, France

  • CHU Besancon

    Besançon, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Caen

    Caen, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Dijon

    Dijon, France

  • CHU Fort-de-France

    Fort-de-France, Martinique

  • CHU Grenoble

    Grenoble, France

  • CHU Lille

    Lille, France

  • CHU Limoges

    Limoges, France

  • CHU Montpellier

    Montpellier, France

  • CHU Nancy

    Nancy, France

  • CHU Nantes

    Nantes, France

  • CHU Nice

    Nice, France

  • CHU Nîmes

    Nîmes, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rennes

    Rennes, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse

    Toulouse, France

  • CHU Tours

    Tours, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Fondation Rothschild

    Paris, France

  • Hôpital Saint Antoine

    Paris, France

  • Hôpital de la Pitié-Salpêtrière

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.